Genomic drivers of resistance to ar therapies
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:

Access through your institution Buy or subscribe Researchers in Canada have identified genomic drivers of resistance to androgen-receptor (AR)-directed therapies in men with metastatic
castration-resistant prostate cancer (mCRPC). Annala _ et al_. performed whole-exome and/or deep targeted sequencing of plasma-derived cell-free DNA samples from 202 treatment-naive men with
mCRPC randomly assigned to abiraterone or enzalutamide. Defects in _BRCA2_ and _ATM_ were associated with poor clinical outcomes independently of clinical prognostic factors and abundance
of circulating tumour DNA. Deleterious alterations in _TP53_ were also associated with reduced time to progression. This is a preview of subscription content, access via your institution
ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time
Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access
to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our
FAQs * Contact customer support REFERENCES * Annala, M. _ et al_. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. _Cancer
Discov._ https://doi.org/10.1158/2159-8290.CD-17-0937 (2018) Article CAS Google Scholar Download references Authors * Rebecca Kelsey View author publications You can also search for this
author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kelsey, R. Genomic drivers of resistance to AR therapies. _Nat Rev Urol_
15, 202 (2018). https://doi.org/10.1038/nrurol.2018.18 Download citation * Published: 13 February 2018 * Issue Date: April 2018 * DOI: https://doi.org/10.1038/nrurol.2018.18 SHARE THIS
ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative